Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 16/20 | 0.63 |
| ▸ | KDR | P35968 | 12/20 | 0.59 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517461 | 0.94 | CSF1R (0.55) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4499928 | 0.93 | PDGFRB (0.55) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4506491 | 0.89 | PDGFRB (0.58) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4507111 | 0.88 | PDGFRB (0.49) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4502699 | 0.86 | CSF1R (0.69) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4494256 | 0.85 | CSF1R (0.65) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4503657 | 0.84 | CSF1R (0.66) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4514269 | 0.80 | PDGFRB (0.60) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4494491 | 0.79 | PDGFRB (0.57) | CSF1RPDGFRBKDRMETPDGFRA | |
| SCHEMBL4504121 | 0.79 | PDGFRB (0.62) | CSF1RPDGFRBKDRMETPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | CSF1R 588/4885PDGFRB 1820/4885KDR 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.